2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

According to DSM Group estimates, the scope of the regional DRP regulated by the
Government Decree No. 890 of July 30, 1994, is comparable to the federal one. The
constituent entities of the Russian Federation form their own lists of regional benefitentitled
social categories.
According to the DSM Group report, in 2020, 174 million packages of medicines worth RUB
233 billion were purchased for benefit-entitled categories of citizens, the decrease compared
to 2019 is 8% in rubles and 9% in packages.
DRP dynamics, RUB bln
DRP dynamics, mln packages
(+6%) (+6.7%) (+2.9%)
(+28.7%)
(-7.8%)
(-3.7%)
(+16.6%) (-6.7%)
(+21.6%)
(-9.3%)
2016 2017 2018 2019 2020
2016 2017 2018 2019 2020
Source: DSM Group
Source: DSM Group
In the DRP segment, one may see the growth of the regional pharmaceutical benefits’ share,
which accounts for more than half of the financing of the subsidized segment. By the end of
2020, the share of High-Cost ICD program also increased – to 28%, while the share of funds
for drugs under general ICD codes, which previously amounted to about 30%, decreased to
18% in 2020.
The ratio between localized and imported drugs in monetary terms in the DRP segment
remains in favor of the imported ones. In 2020, their share is 63% of the sales value, while
domestic drugs account for only 37%. This is due to the fact that under the DRP programs it is
usually the original expensive and most often imported drugs that are purchased.
The DRP segment is mainly represented by prescription drugs: at the end of 2020, their share
in value terms was 96.8% (+0.7% compared to 2019), in volume terms – 92.3% (+0.8%).
RUSSIAN-FINNISH LIFE SCIENCE INDUSTRY
Research and export directory
19